Early research (Phase 1)Study completedNCT02940522
What this trial is testing
Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
Who this might be right for
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
AMAG Pharmaceuticals, Inc. 122